The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Eli Lilly continues to break new ground. Its famous weight loss medicine, Zepbound (tirzepatide), just became the first to ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo ...

President-elect Donald Trump has asked the Supreme Court to delay implementation of the law banning TikTok. Western officials say North Korean soldiers are dying in high numbers along the Ukrainian ...